Cargando…

Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein

Calcium-permeable pores formed by small oligomers of amyloid proteins are the primary pathologic species in Alzheimer’s and Parkinson’s diseases. However, the molecular mechanisms underlying the assembly of these toxic oligomers in the plasma membrane of brain cells remain unclear. Here we have anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Scala, Coralie, Yahi, Nouara, Boutemeur, Sonia, Flores, Alessandra, Rodriguez, Léa, Chahinian, Henri, Fantini, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926208/
https://www.ncbi.nlm.nih.gov/pubmed/27352802
http://dx.doi.org/10.1038/srep28781
_version_ 1782440067696951296
author Di Scala, Coralie
Yahi, Nouara
Boutemeur, Sonia
Flores, Alessandra
Rodriguez, Léa
Chahinian, Henri
Fantini, Jacques
author_facet Di Scala, Coralie
Yahi, Nouara
Boutemeur, Sonia
Flores, Alessandra
Rodriguez, Léa
Chahinian, Henri
Fantini, Jacques
author_sort Di Scala, Coralie
collection PubMed
description Calcium-permeable pores formed by small oligomers of amyloid proteins are the primary pathologic species in Alzheimer’s and Parkinson’s diseases. However, the molecular mechanisms underlying the assembly of these toxic oligomers in the plasma membrane of brain cells remain unclear. Here we have analyzed and compared the pore-forming capability of a large panel of amyloid proteins including wild-type, variant and truncated forms, as well as synthetic peptides derived from specific domains of Aβ1-42 and α-synuclein. We show that amyloid pore formation involves two membrane lipids, ganglioside and cholesterol, that physically interact with amyloid proteins through specific structural motifs. Mutation or deletion of these motifs abolished pore formation. Moreover, α-synuclein (Parkinson) and Aβ peptide (Alzheimer) did no longer form Ca(2+)-permeable pores in presence of drugs that target either cholesterol or ganglioside or both membrane lipids. These results indicate that gangliosides and cholesterol cooperate to favor the formation of amyloid pores through a common molecular mechanism that can be jammed at two different steps, suggesting the possibility of a universal therapeutic approach for neurodegenerative diseases. Finally we present the first successful evaluation of such a new therapeutic approach (coined “membrane therapy”) targeting amyloid pores formed by Aβ1-42 and α-synuclein.
format Online
Article
Text
id pubmed-4926208
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-49262082016-07-01 Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein Di Scala, Coralie Yahi, Nouara Boutemeur, Sonia Flores, Alessandra Rodriguez, Léa Chahinian, Henri Fantini, Jacques Sci Rep Article Calcium-permeable pores formed by small oligomers of amyloid proteins are the primary pathologic species in Alzheimer’s and Parkinson’s diseases. However, the molecular mechanisms underlying the assembly of these toxic oligomers in the plasma membrane of brain cells remain unclear. Here we have analyzed and compared the pore-forming capability of a large panel of amyloid proteins including wild-type, variant and truncated forms, as well as synthetic peptides derived from specific domains of Aβ1-42 and α-synuclein. We show that amyloid pore formation involves two membrane lipids, ganglioside and cholesterol, that physically interact with amyloid proteins through specific structural motifs. Mutation or deletion of these motifs abolished pore formation. Moreover, α-synuclein (Parkinson) and Aβ peptide (Alzheimer) did no longer form Ca(2+)-permeable pores in presence of drugs that target either cholesterol or ganglioside or both membrane lipids. These results indicate that gangliosides and cholesterol cooperate to favor the formation of amyloid pores through a common molecular mechanism that can be jammed at two different steps, suggesting the possibility of a universal therapeutic approach for neurodegenerative diseases. Finally we present the first successful evaluation of such a new therapeutic approach (coined “membrane therapy”) targeting amyloid pores formed by Aβ1-42 and α-synuclein. Nature Publishing Group 2016-06-29 /pmc/articles/PMC4926208/ /pubmed/27352802 http://dx.doi.org/10.1038/srep28781 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Di Scala, Coralie
Yahi, Nouara
Boutemeur, Sonia
Flores, Alessandra
Rodriguez, Léa
Chahinian, Henri
Fantini, Jacques
Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein
title Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein
title_full Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein
title_fullStr Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein
title_full_unstemmed Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein
title_short Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein
title_sort common molecular mechanism of amyloid pore formation by alzheimer’s β-amyloid peptide and α-synuclein
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926208/
https://www.ncbi.nlm.nih.gov/pubmed/27352802
http://dx.doi.org/10.1038/srep28781
work_keys_str_mv AT discalacoralie commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein
AT yahinouara commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein
AT boutemeursonia commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein
AT floresalessandra commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein
AT rodriguezlea commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein
AT chahinianhenri commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein
AT fantinijacques commonmolecularmechanismofamyloidporeformationbyalzheimersbamyloidpeptideandasynuclein